These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6542790)

  • 21. Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
    Kris MG; Gralla RJ; Kelsen DP; Casper ES; Burke MT; Fiore JJ; Cibas IR; Heelan RT
    Am J Clin Oncol; 1985 Oct; 8(5):377-9. PubMed ID: 3864366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
    Bogush T; Robert J
    Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haematotoxicity of doxorubicin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and of their association in rats.
    Lahouel M; Viotte G; Sumereau E; Morin JP; Fillastre JP
    Drugs Exp Clin Res; 1987; 13(10):593-9. PubMed ID: 3428123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration.
    Solem LE; Henry TR; Wallace KB
    Toxicol Appl Pharmacol; 1994 Dec; 129(2):214-22. PubMed ID: 7527602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.
    Geroni C; Ripamonti M; Arrigoni C; Fiorentini F; Capolongo L; Moneta D; Marchini S; Della Torre P; Albanese C; Lamparelli MG; Ciomei M; Rossi R; Caruso M
    Cancer Res; 2001 Mar; 61(5):1983-90. PubMed ID: 11280756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
    Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
    Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NTP technical report on the toxicity studies of methacrylonitrile (CAS No. 126-98-7). Administered by gavage to F344/N rats and B6C3F1 mice.
    Ghanayem BI
    Toxic Rep Ser; 2000 May; (47):1-56, A1-E6. PubMed ID: 11803706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
    Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
    Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The discovery of daunorubicin.
    Di Marco A; Cassinelli G; Arcamone F
    Cancer Treat Rep; 1981; 65 Suppl 4():3-8. PubMed ID: 7049379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
    Taatjes DJ; Fenick DJ; Koch TH
    Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
    Kogan NM; Schlesinger M; Peters M; Marincheva G; Beeri R; Mechoulam R
    J Pharmacol Exp Ther; 2007 Aug; 322(2):646-53. PubMed ID: 17478614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias.
    Sessa C; Tschopp L; Fopp M; Cavalli F
    Invest New Drugs; 1985; 3(4):357-9. PubMed ID: 3866755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
    Robert J
    Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NTP Toxicology and Carcinogenesis Studies of 2,2-Bis(Bromomethyl)-1,3-Propanediol (FR-1138(R)) (CAS No. 3296-90-0) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 May; 452():1-465. PubMed ID: 12594523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin.
    Minderman H; Linssen P; Wessels J; Haanen C
    Anticancer Res; 1993; 13(4):1161-5. PubMed ID: 8352539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and antitumor activity of optically active (+)-9-O-alpha-L-daunosaminyl-4-demethoxydaunorubicin.
    Kimura Y; Matsumoto T; Suzuki M; Terashima S
    J Antibiot (Tokyo); 1985 Sep; 38(9):1277-9. PubMed ID: 4066509
    [No Abstract]   [Full Text] [Related]  

  • 38. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity.
    Pereverzeva E; Treschalin I; Bodyagin D; Maksimenko O; Langer K; Dreis S; Asmussen B; Kreuter J; Gelperina S
    Int J Pharm; 2007 Jun; 337(1-2):346-56. PubMed ID: 17306479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radionuclide angiographic monitoring in patients treated with potentially cardiotoxic cytostatic drugs.
    Vorobiof DA; Falkson G; Iturralde MP
    S Afr Med J; 1988 Sep; 74(5):213-6. PubMed ID: 3166211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Toxicity of rubomycin 13-cyclohexylidene hydrazone].
    Stepanova ES; Vertogradova TP; Shevniuk LA; Shepelevtseva NG; Gol'dberg LE
    Antibiot Med Biotekhnol; 1987 Jan; 32(1):42-7. PubMed ID: 3566228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.